• Main
  • Useful links
  • Information for Contributors
  • About
  • Editorial board

    •
    Bulletin of problems biology and medicine / Issue 3 part 2 (111), 2014 / Microalbuminuria is an Early Diagnostic and Clinical Marker for Prognosis of Target Organ Damage in Arterial Hypertension

    Grona N. V.

    Microalbuminuria is an Early Diagnostic and Clinical Marker for Prognosis of Target Organ Damage in Arterial Hypertension

    About the author:

    Grona N. V.

    Heading:

    LITERATURE REVIEWS

    Type of article:

    Scentific article

    Annotation:

    The prevalence of hypertension, chronic kidney disease and end­stage renal disease attributable to hypertension continues to rise worldwide. Identifying the precise prevalence of chronic kidney disease attributable to hypertension is difficult owing to the absence of uniform criteria to establish a diagnosis of hypertensive nephropathy. Essential hypertension usually clusters with other cardiovascular risk factors such as age, overweight, diabetes, insulin resistance and dyslipidemia. The target organ damage such as left ventricular hypertrophy, hypertensive nephropathy, acute coronary syndrome, stroke and cognitive dysfunction takes place early in course of hypertension. Though the prevalence of hypertension is high, the relationship between microalbuminuria and target organ damage in hypertension is not well studied. Microalbuminuria is a strong and independent indicator of increased cardiovascular risk among individuals with and without diabetes. Therefore, microalbuminuria can be used for stratification of risk for cardiovascular disease. At present, the most likely possibility is that a common pathophysiologic process, such as endothelial dysfunction, chronic low­grade inflammation, or increased transvascular leakage of macromolecules, underlies the association between microalbuminuria and cardiovascular disease, but more and prospective studies of these hypotheses are needed. Albumin is a relatively large, negatively charged protein. The filter through which albumin must pass before entering the urine, the glomerular capillary wall, is size and charge selective. Microalbuminuria is thought to be a consequence of an increased albumin leakage through the glomerular capillary wall as a result of increased permeability of the wall, an increased intraglomerular pressure, or both. For example, hyperglycemia and high blood pressure are generally accepted risk factors for development of microalbuminuria. Both can increase intraglomerular pressure. They can alter the charge selectivity of the glomerular capillary wall, thereby increasing its permeability. In a healthy kidney >99 % of filtered albumin is reabsorbed in the proximal tubules. Some data suggest that microalbuminuria, at least in patients with hypertension and type 2 diabetes, is associated not only with increased glomerular protein passage but also with an absence of a compensatory increase in tubular reabsorption of albumin. A pronounced increase in albumin filtered by the glomerulus will lead to excessive supply of albumin to the renal tubule, eventually exceeding tubular reabsorptive capacity, and thus to increased albumin excretion in the urine. Theoretically, endothelial dysfunction could cause albuminuria by increasing glomerular pressure and glomerular barrier permeability. Endothelial dysfunction can be defined as any change in endothelial properties that is inappropriate with regard to the preservation of organ function. The findings support the concept that impaired endothelial nitric oxide synthesis plays a role in the association of microalbuminuria with cardiovascular disease risk. This is reflected by expressions such as “microalbuminuria is a risk indicator for cardiovascular disease”, and “microalbuminuria is a marker of endothelial dysfunction” and early stage of hypertensive nephropathy. Once microalbuminuria is present, cardiovascular risk factor reduction should be more “aggressive”. Early screening of patients with essential hypertension for microalbuminuria and aggressive management of positive cases might reduce the burden of chronic kidney diseases and cardiovascular diseases in the community.

    Tags:

    arterial hypertension, microalbuminuria

    Bibliography:

    • Аракелянц а. а. Микроальбуминурия: клиническое и прогностическое значение при артериальной гипертонии / а. а. аракелянц, н. В. Жукова, а. с. рязанов // терапевтический архив. – 2003. – т. 75. – с. 47­82.
    • Бурмагина а. г. ассоциация предгипертензии с факторами риска хронической болезни почек, гипертонической бо­ лезни и атеросклероза / а. г. бурмагина, а. Ю. николаев // клиническая нефрология. – 2012. – № 5­6. – с. 15­18.
    • Виллевальде с. В. значение оценки функционального состояния почек для реклассификации больных неосложнен­ ной артериальной гипертонией по сердечно­сосудистому риску / с. В. Виллевальде, е. а. тюхменев, Ж. д. кобала­ ва // Эффективная фармакотерапия в кардиологии и ангиологии. – 2010. – № 3. – с. 20­25.
    • Карпачева н. а. Возможности ранней диагностики хронической болезни почек у подростков при диспансеризации / н. а. карпачева, Э. к. петросян // клиническая нефрология. – 2013. – № 1. – с. 44­48.
    • Моисеев В. с. кардиоренальные синдромы (патогенетические, клинико­диагностические и терапевтические аспек­ ты) / В. с. Моисеев, Ж. д. кобалава // терапевтический архив. – 2011. – № 12. – с. 5­11.
    • Морозов Ю. а. клиническое значение микроальбуминурии в практике врача. пособие для врачей / Ю. а. Морозов, и. и. дементьева, М. а. чарная; под общей ред. Морозова Ю. а. – М.: «Мед­М», 2010. – 28 с.
    • Мухин н. а. нефропротективная стратегия. В кн.: нефрология. рук­во для врачей / н. а. Мухин, В. В. Фомин; под об­ щей ред. е. М. Шилова. – M.: гЭотар­Медиа, 2007. – с. 629­644.
    • нанчикеева М. л. клиническое значение определения в моче маркеров эндотелиальной дисфункции и фиброгенеза у больных артериальной гипертензией с поражением почек / М. л. нанчикеева, л. В. козловская, В. В. Фомин // кли­ ническая нефрология. – 2009. – № 4. – с. 54­58.
    • николаев а. Ю. Возможности и перспективы нефропротективной стратегии / а. Ю. николаев // терапевтический ар­ хив. – 2012. – № 6. – с. 77–80.
    • николаев а. Ю. нефропротективная стратегия: влияние на прогрессирование хронической болезни почек. В кн.: ле­ чение почечной недостаточности. рук­во для врачей / а. Ю. николаев, Ю. с. Милованов. – М.: Медицинское инфор­ мационное агентство, 2011. – с. 226­279.
    • ребров а. п. дисфункция почек у больных артериальной гипертензией при наличии и отсутствии сопутствующей па­ тологии / а. п. ребров, а. л. куклина // клиническая нефрология. – 2013. – № 5. – с. 13­18.
    • 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hy­ pertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // Journal of Hypertension. – 2013. – Vol. 31(7). – р. 1281­1357.
    • 2014 Evidence­Based Guideline for the Management of High Blood Pressure in Adults. Report From the Panel Members Ap­ pointed to the Eighth Joint National Committee (JNC 8) // JAMA. – 2014. – Vol. 311(5). – р. 507­520.
    • Badiger S. Microalbuminuria in Essential Hypertension / S. Badiger, P. T. Akkasaligar, H. M. Sandeep // International Science Index. – 2011. – Vol. 1­5 (12). – р. 1928­1932.
    • Badiger S. A Study of Microalbuminuria and Target Organ Damage in Patients with Essential Hypertension / S. Badiger, H. M. Sandeep, S. C. Talikoti // Int. J. Biol. аnd Med. Res. – 2012. – Vol. 3(1). – р. 1351­1355.
    • Basi S. Microalbuminuria as a target to improve cardiovascular and renal outcomes / S. Basi, J. B. Lewis // Am. J. of Kidney Dis. – 2006. – Vol. 47(6). – р. 927­946.
    • Bohm M. Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i­SEARCH global study / M. Bohm, M. Thoenes, N. Danchin [et al.] // Journal of Hypertension. – 2007. – Vol. 25. – р. 2317­2324.
    • Cohuet G. Mechanisms of target organ damage caused by hypertension: therapeutic potential / G. Cohuet, H. Struijker­ Boudier // Pharmacology and Therapeutics. – 2006. – Vol. 111. – р. 81­98.
    • Diabetes Management Guidelines American Diabetes Association (ADA) 2013. Guidelines аmerican Diabetes Association. Standards of medical care in diabetes­2013 // Diabetes Care. – 2013. – Vol. 36(1). – р. 11­66.
    • Diseases of Renal Parenchyma /Edited by Prof. Manisha Sahay. – InTech, 2012. – 304 р.
    • Haase M. NGAL­From discovery to a new era of “Acute Renal Disease” diagnosis? / M. Haase // Clin. Biochem. – 2011. – Vol. 44(7). – р. 499­500.
    • Heart Disease and Stroke Statistics­2013 Update A Report From the American Heart Association // Circulation. – 2013. – Vol. 127. – р. 6­245.
    • Hillege H. L. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population / H. L. Hillege, V. Fidler, G. F. Diercks [et al.] // Circulation. – 2002. – Vol. 106. – р. 1777­1782.
    • Iseki Kunitoshi Proteinuria and the risk of developing end­stage renal disease / Iseki Kunitoshi, Ikemiya Yoshiharu, Iseki Chi­ ho // Kidney International. – 2003. – Vol. 63. – р. 1468­1474.
    • James M. T. Early recognition and prevention of chronic kidney disease / M. T. James, B. R. Hemmelgarn, M. Tonelli // Lancet. – 2010. – Vol. 375(9722). – р. 1296­1309.
    • Leoncini G. Chronic Kidney Disease and Albuminuria in Arterial Hypertension / G. Leoncini, F. Viazzi, R. Pontremoli // Current Hypertension Reports. – 2010. – Vol. 12(5). – р. 335­341.
    • Ljutic D. The role of arterial hypertension in the progression of non­diabetic glomerular diseases / D. Ljutic, P. Kes // Nephrol. Dial. Transpl. – 2003. – Vol. 18. – р. 28­30.
    • Locatelli F. The importance of early detection of chronic kidney disease / F. Locatelli, L. D. Vecchio, P. Pozzoni // Nephr. Dial. Transpl. – 2002. – Vol. 17(11). – р. 2­7.
    • Lock E. A. Sensitive and early markers of renal injury: where are we and what is the way forward? / E. A. Lock // Toxicology Sciences. – 2010. – Vol. 116(1). – р. 1­4.
    • Mahmoodi B. K. Associations of kidney disease measures with mortality and end­stage renal disease in individuals with and without hypertension: a meta­analysis / B. K. Mahmoodi, K. Matsushita, M. Woodward [et al.] // Lancet. – 2012. – Vol. 380. – р. 1649­1661.
    • Montaсйs B. R. Recommendations on assessing proteinuria during the diagnosis and follow­up of chronic kidney disease / B. R. Montaсйs, G. S. Grаcia, S. D. Pйrez [et al.] // Nefrologia. – 2011. – Vol. 31(3). – р. 331­345.
    • Navar L. G. The kidney in blood pressure regulation. In: Atlas of Diseases of the Kidney. Hypertension and the Kidney / L. G. Navar, L. L. Hamm. – Wilcox CS. Philadelphia: Current Medicine, Inc., 1999. – р. 1. 1­1. 22.
    • Pollak J. Microalbuminuria and risk of cardiovascular diseases in patients with diabetes and hypertension / J. Pollak, G. Sypniewska // Biochemia Medica. – 2008. – Vol. 18(2). – р. 25­34.
    • Pontremoli R. Prevalence and clinical correlates of microalbuminuria in essential hypertension. The MAGIC study / R. Pontre­ moli, A. Sofia, M. Ravera // Hypertension. – 1997. – Vol. 30. – р. 1135­1143.
    • Ritz е. Renal dysfunction as a novel risk factor (Microalbuminuria and cardiovascular risk) / е. Ritz // кidney Int. Suppl. – 2005. – Vol. 93. – р. 25­28.
    • Ronco C. Cardio­renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative / C. Ronco, P. McCullough, S. Anker [et al.] // Eur. Heart. J. – 2010. – Vol. 31. – р. 703­711.
    • Smink P. A. Albuminuria, estimated GFR, traditional risk factors, and incident cardiovascular disease: the PREVEND (Pre­ vention of Renal and Vascular Endstage Disease) study / P. A. Smink, Heerspink H. J. Lambers, R. T Gansevoort [et al.] // Am. J. Kidney Dis. – 2012. – Vol. 60. – р. 804­811.
    • Staples A. Risk factors for progression of chronic kidney disease / A. Staples, C. S. Wong // Current Opinion in Pediatrics. – 2011. – Vol. 22(2). – р. 161­169.
    • Tesch G. H. Review: Serum and urine biomarkers of kidney disease: A pathophysiological perspective / G. H. Tesch [et al.] // Nephrology. – 2010. – Vol. 15. – р. 609­616.
    • Udani S. Epidemiology of hypertensive kidney disease. Nature Reviews / S. Udani, I. Lazich, G. L. Bakris // Nephrology. – 2010. – Vol. 7(1). – р. 11­21.
    • Viazzi F. Microalbuminuria Is a Predictor of Chronic Renal Insufficiency in Patients without DM and with Hypertension: The MAGIC Study / F. Viazzi, G. Leoncini, N. Conti [et al.] // Clinical Journal of the American Society of Nephrology. – 2010. – Vol. 5. – р. 1099­1106.
    • Volpe M. Microalbuminuria Screening in Patients With Hypertension: Recommendations for Clinical Practice / M. Volpe // Int. J. Clin. Pract. – 2008. – Vol. 62(1). – р. 97­108.
    • Zhang а. Progress in Pathogenesis of Proteinuria / а. Zhang, S. Huang // Int. J. Nephrol. – 2012. – Vol. 12. – р. 314­251.

    Publication of the article:

    «Bulletin of problems biology and medicine» Issue 3 part 2 (111), 2014 year, 11-16 pages, index UDK 612. 12­008. 331+616. 61­008. 64]:612. 466. 22